Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin and Zanubrutinib with R-CHP in Non-GCB DLBCL
NCT06468943Phase 2Enrolling by invitation
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2023
- Primary completion
- May 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin, zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Soochow University. Started Jul 2023; status: enrolling by invitation.
02
Drugs
polatuzumab vedotinzanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06468943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468943.